Business
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results
VANCOUVER, BC, Feb. 11, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical
About this update from Inmed Pharmaceuticals Inc.
[{"type":"text","content":"VANCOUVER, BC, Feb. 11, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (\"CBN\"), today reported financial results for the second quarter of fiscal year 2021 (\"2Q21\") which ended December 31, 2020.\nConference Call & Webcast1:\nThursday, February 11, 2021 at 8:30 AM Pacific Time, 11:30 AM Eastern Time\nLocal - Toronto\n(+1) 416-764-8609 \nLocal - Vancouver \n(+1) 778-383-7417\nToll Free - North America\n(+1) 888-390-0605 \nConference ID:\n19917866\nWebcast: https://produceredition.webcasts.com/starthere.jsp?ei=1425283&tp_key=9f171376cb \n(1Webcast replay available for 90 days) \nDial-In Replays2:\nToronto:\n(+1) 416-764-8677\nNorth America (Toll Free):\n(+1) 888-390-0541\nPlayback Passcode:\n 917866 #\n(2Dial-in replay available till February 18, 2021)\nThe Company's 10-Q including financial statements and related MD&A for the second quarter ending December 31, 2020 are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.\n\"The second quarter of fiscal 2021 saw InMed achieve several key, value-adding and risk mitigating milestones across both its therapeutic programs and IntegraSynTM manufacturing approach,\" said InMed President and Chief Executive Officer, Eric A. Adams. \"We now have a strong body of safety and tolerability data for INM-755, which is the basis for our plans to commence safety and efficacy trials in Epidermolysis Bullosa patients this calendar year. We announced business development activities in both our ocular therapeutic and our innovative, biosynthesis-based IntegraSynTM manufacturing program this last quarter. These announcements are a reflection of our increased emphasis on business development activities as an avenue to advance our R&D efforts.\"\nResearch & Development Update:\nINM-755 for the Treatment of Epidermolysis Bullosa (\"EB\"):\nOn November 25, 2020, InMed announced top-line results from its 755-101-HV Phase 1 clinical trial (\"Study 101\"). Study 101 was a randomized, vehicle-controlled, double-blind, Phase 1 trial, that examined the safety and tolerability of two strengths of INM-755 cream on intact skin in 22 healthy adult volunteers over a 14-day...